Healthcare / Medical DevicesShenzhen
$14.20
+0.25 (+1.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $75.9M · quality 75.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.3B
P/E
645.5x
↑EV/EBITDA
39.1x
↑ROE
0.3%
↓Gross Margin
69.6%
↑Debt/Equity
0.28
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-20.2%
FCF CAGR
-8.1%
FCF margin
20.9%
FCF / Net income
21.15x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $363.8M · net income $3.6M · FCF $75.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $363.8M | $363.8M | $436.8M | $542.8M | $716.0M |
| Net Income | $3.6M | $3.6M | $34.5M | $89.4M | $124.8M |
| EBITDA | $59.5M | $59.5M | $103.0M | $166.4M | $212.2M |
| EPS | 0.02 | 0.02 | 0.21 | 0.55 | 0.77 |
| Gross Margin | 69.6% | 69.6% | 66.1% | 65.3% | 57.0% |
| Operating Margin | 10.6% | 10.6% | 14.7% | 13.9% | 13.6% |
| Net Margin | 1.0% | 1.0% | 7.9% | 16.5% | 17.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.28 | 0.28 | 0.07 | 0.01 | 0.01 |
| Current Ratio | 5.38 | 5.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $75.9M | $75.9M | $78.1M | $25.1M | $97.8M |
| Returns | |||||
| ROE | 0.3% | 0.3% | 2.3% | 5.8% | 8.5% |
| Valuation | |||||
| P/E | 645.45 | 645.45 | 62.86 | 31.42 | 27.85 |
| EV/EBITDA | 39.14 | 39.14 | 19.05 | 14.60 | 15.33 |
| P/B | 1.62 | 1.62 | 1.44 | 1.84 | 2.36 |
| Growth & Yield | |||||
| Revenue Growth | -16.7% | -16.7% | -19.5% | -24.2% | — |
| EPS Growth | -89.7% | -89.7% | -61.1% | -28.6% | — |
| Dividend Yield | 0.7% | 0.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
285.5%
EPS terminal req.
$1.26
Spread vs growth
-375.1%
5Y implied EPS CAGR
133.4%
EPS terminal req.
$1.52
Spread vs growth
-223.1%
10Y implied EPS CAGR
60.2%
EPS terminal req.
$2.46
Spread vs growth
-149.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.8%
Start / end P/E
66.0x → 645.5x
EPS bridge
0.21 → 0.02
Residual
-787.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.